SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors weigh strong AI and Cloud infrastructure growth against a recent technical pullback ahead of the company's upcoming earnings release. The community remains focused on whether recent insider buying and the company's AI-RAN technology will act as catalysts to overcome near-term margin concerns and drive a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing heavy attention as investors anticipate a major Phase 3 REGAL trial readout, with community discourse centered on the approaching 80th event milestone and the potential for a transformative partnership or buyout. While supporters emphasize strong long-term survival data and a robust institutional presence, the stock remains a focal point for intense debate, characterized by high volatility and conflicting perspectives on trial efficacy versus potential dilution risks.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending after reporting strong Q2 results that topped expectations across revenue and EPS, effectively challenging the narrative that AI adoption would erode demand for enterprise software. The community is actively debating the company's guidance and long-term potential, with bulls pointing to the billion-dollar AI contract milestone and management's upbeat tone as evidence of durable growth.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors scrutinize the company's aggressive capital expenditure on AI infrastructure versus its earnings performance. The community is sharply divided, with bulls pointing to accelerating cloud revenue and enterprise adoption, while bears express concern over rising costs and the impact of capital spending on free cash flow.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing volatility as investors weigh a strong revenue beat and 82% cloud growth against concerns over massive capital expenditure increases and negative free cash flow. While the community is debating whether the AI infrastructure spending is a necessary long-term investment or a sign of an overvalued sector, many are focused on the massive cloud backlog as evidence of sustained enterprise AI demand.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as analysts issue a series of price target increases following strong earnings results and a raised full-year outlook. The community is actively discussing the company's operational strength, its successful capital return strategy, and its strategic pivot toward premium gasoline-powered vehicles alongside defense-sector expansion.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing significant downward pressure as investors grow anxious about massive upcoming share unlocks and poor broader market sentiment surrounding Elon Musk's companies. Community members are divided between those looking for a long-term bottom and those actively shorting the stock, while all eyes remain fixed on the upcoming Starship test flight as a potential catalyst for volatility.

WorldFinancial

WorldFinancial (WLFI) is trending as investors debate whether the current price represents a value-buying opportunity or an ongoing decline following significant token sell-offs. Community sentiment is deeply divided between those citing a supply shock and potential token burns as catalysts for a rebound, and others labeling the project a grift linked to the Trump family.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The Other segment includes DLP products, calculators, and custom application-specific integrated circuits products. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments reported a mixed quarterly result with a slight earnings and revenue miss, yet the stock surged as management issued bullish forward guidance citing recovery in industrial and data center demand. Investors are currently debating whether this price action represents a sustainable turnaround or an overextension, while closely monitoring the company's capital expenditure strategy and its exposure to long-term semiconductor trends.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing a surge in trading volume and institutional accumulation, with the community actively debating whether this signals a genuine breakout or continued algorithmic manipulation. Investors are closely watching the stock's significant short interest and strategic pivot toward agentic AI, positioning it as a volatile battleground as they await catalysts that could trigger a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Centene (CNC) Outpaced Other Medical Stocks This Year?

Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data

Equity

The biotech firm reported strong Phase 2 trial results for a blood cancer treatment, along with a $140 million fundraise to support the next stages of the trial.

Insider Signals and Potential Moonshots that Could Reset Valuations

Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP

Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.read more...

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

Insights into Cellectar Biosciences's Upcoming Earnings

Earnings Outlook For Cellectar Biosciences

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Cellectar Biosciences Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.47
Prev Close	$2.58
Open	$2.54
Dividend Yield	0.00%
50-Day Moving Average	$2.73
Beta	0.93
Avg. Volume	156,640.00
PE Ratio	-0.33

52-Week High	$6.52
52-Week Low	$2.20
Market Capitalization	$20.62M
EPS (Annual)	-$8.35
Price to Book	3.72
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLRBCellectar Biosciences Inc

Latest CLRB News